Macquarie Group Ltd. Sells 209,905 Shares of Merck & Co., Inc. (MRK)
Macquarie Group Ltd. trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,543,744 shares of the company’s stock after selling 209,905 shares during the period. Merck & Co. accounts for 1.4% of Macquarie Group Ltd.’s portfolio, making the stock its 16th biggest position. Macquarie Group Ltd. owned approximately 0.46% of Merck & Co. worth $797,029,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Vigilant Capital Management LLC grew its stake in Merck & Co. by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares during the period. Harbour Capital Advisors LLC bought a new stake in Merck & Co. in the first quarter worth $127,000. Gradient Investments LLC boosted its holdings in Merck & Co. by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after acquiring an additional 674 shares in the last quarter. Pinnacle Bank bought a new stake in Merck & Co. in the first quarter worth $152,000. Finally, Dillon & Associates Inc. bought a new stake in Merck & Co. in the first quarter worth $206,000. 73.02% of the stock is currently owned by institutional investors.
Merck & Co., Inc. (NYSE MRK) traded up 0.560% during mid-day trading on Tuesday, reaching $65.495. The company had a trading volume of 3,109,010 shares. The firm has a market capitalization of $178.63 billion, a PE ratio of 35.460 and a beta of 0.81. The stock’s 50-day moving average price is $62.98 and its 200 day moving average price is $63.69. Merck & Co., Inc. has a 52 week low of $58.29 and a 52 week high of $66.80.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & Co. had a return on equity of 19.69% and a net margin of 19.65%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $0.93 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post $3.87 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.89%. Merck & Co.’s dividend payout ratio is currently 76.11%.
MRK has been the topic of several analyst reports. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $74.00 target price (up from $70.00) on shares of Merck & Co. in a report on Thursday, July 27th. Citigroup Inc. set a $65.00 target price on Merck & Co. and gave the stock a “hold” rating in a report on Wednesday, July 5th. Zacks Investment Research raised Merck & Co. from a “hold” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Friday, May 26th. BidaskClub downgraded Merck & Co. from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, Piper Jaffray Companies set a $70.00 target price on Merck & Co. and gave the stock a “buy” rating in a report on Saturday, July 29th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $70.00.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related stocks with our FREE daily email newsletter.